

Aberrations of 6q13 mapped to the *COL12A1* locus in chondromyxoid fibroma

Taketoshi Yasuda^{1,7}, Jun Nishio^{1,7}, Janos Sumegi², Kayla M Kapels¹, Pamela A Althof¹, Jeffrey R Sawyer³, John D Reith⁴ and Julia A Bridge^{1,5,6}

¹Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, USA;

²Department of Pediatrics, Cincinnati Children's Hospital, Cincinnati, OH, USA; ³Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, AR, USA; ⁴Department of Pathology, Immunology, and Laboratory Medicine, Unit of Bone and Soft Tissue Pathology, University of Florida Health Sciences, Gainesville, FL, USA; ⁵Department of Pediatrics, University of Nebraska Medical Center, Omaha, NE, USA and ⁶Department of Orthopaedic Surgery, University of Nebraska Medical Center, Omaha, NE, USA

Chondromyxoid fibroma, a rare benign bone tumor, may be mistaken for chondrosarcoma. Although cytogenetic studies of chondromyxoid fibroma are few, rearrangements of the long arm of chromosome 6, frequently expressed as an *inv(6)(p25q13)*, are prominent. In this study, conventional cytogenetic analysis of 16 chondromyxoid fibroma samples from 14 patients revealed rearrangements of chromosome 6 in 10 of 11 clonally abnormal specimens. In addition to 6q13 rearrangements, recurrent 6p25 and 6q25 anomalies were detected. Notably, an identical *t(6;9)(q25;q22)* translocation was identified in two cases, suggesting that it represents a distinct translocation of chondromyxoid fibroma. In an effort to further define the aberrant 6q13 breakpoint and identify the molecular consequences, a fluorescence *in situ* hybridization (FISH)-based positional cloning strategy on chondromyxoid fibroma abnormal metaphase and interphase cells using a series of bacterial and plasmid artificial chromosome (BAC/PAC) probe combinations spanning a 6.1 Mb region was employed. The breakpoint on 6q13 was located within the *COL12A1* gene, a collagen gene purportedly involved in another benign bone tumor, subungual exostosis. The findings of this study expand our knowledge of chromosomal alterations in chondromyxoid fibroma, identify *COL12A1* as the likely gene candidate within the recurrent 6q13 breakpoint, and provide an alternative approach for detecting 6q13 anomalies in nondividing cells of chondromyxoid fibroma. The latter could potentially be utilized as an adjunct in diagnostically challenging cases.

Modern Pathology (2009) 22, 1499–1506 doi:10.1038/modpathol.2009.101; published online 31 July 2009

Keywords: chondromyxoid fibroma; cytogenetics; fluorescence *in situ* hybridization; *COL12A1*

Chondromyxoid fibroma is a rare benign tumor of bone that was first described by Jaffe and Lichtenstein¹ in 1948. Chondromyxoid fibroma most commonly arises in the second and third decades of life^{2,3} and typically involves the metaphysis of long bones. Histopathologically, the tumor is characterized by spindle shaped or stellate cells with round to oval nuclei and eosinophilic cytoplasm

embedded in a myxoid or chondroid matrix.⁴ Multinucleated osteoclast-like giant cells are often present at the periphery of the lobules. Approximately 18% of tumors show enlarged, hyperchromatic, and pleomorphic nuclei that may suggest malignancy, in particular chondrosarcoma.³

Few cases of chondromyxoid fibroma have been cytogenetically characterized.^{5–15} Clonal abnormalities of chromosome 6 are prominent and have involved the following three recurrent breakpoints: 6p25, 6q13, and 6q25. A chromosome 6 pericentric inversion involving bands p25 and q13 has been described as the sole anomaly in two chondromyxoid fibromas^{9,12} and as a component of more complex karyotypes in three other chondromyxoid fibromas.^{8,9,11} In this study, an identical

Correspondence: Dr JA Bridge, MD, Department of Pathology and Microbiology, University of Nebraska Medical Center, 983135 Nebraska Medical Center, Omaha, NE 68198-3135, USA.
E-mail: jbridge@unmc.edu

⁷These authors contributed equally to this work.
Received 23 April 2009; revised 13 June 2009; accepted 16 June 2009; published online 31 July 2009

inv(6)(p25q13) was detected in additional chondromyxoid fibroma cases, as also a novel recurrent translocation t(6;9)(q25;q22).¹⁰ Moreover, a detailed molecular cytogenetic investigation of the 6q13 breakpoint strongly suggesting the collagen gene *COL12A1* is the target gene involved is reported.

Materials and methods

Tumor Samples

A total of 16 chondromyxoid fibromas arising in 14 patients, 6 males and 8 females, were included in this study. The clinicopathologic features of the patients and corresponding tumors are listed in Table 1. The karyotypes for three of these patients have been reported previously (cases 8–10).^{8,10} All cases were histologically characterized according to established criteria (Figure 1).²

Cytogenetic Analysis

Cytogenetic analysis was performed on sterile, representative tissue of each case using standard

culture and harvest procedures, as described previously.¹⁶ Briefly, the tissues were disaggregated mechanically and enzymatically, and then cultured in RPMI 1640 medium supplemented with 20% fetal bovine serum for 3–7 days. Cells were exposed overnight to colcemid (0.02 µg/ml). After subsequent hypotonic treatment (0.7% sodium citrate for 20 min), the preparations were fixed three times with methanol and glacial acetic acid (3:1). Metaphase cells were banded with Giemsa trypsin or Wright stain, and the karyotypes were expressed according to the International System for Human Cytogenetic Nomenclature.¹⁷

Probe Design

Molecular cytogenetic studies were conducted to further define the recurrent 6q13 breakpoint. This chromosomal band encompassing a 6.1 Mb region was subdivided into 21 segments that sequentially spanned the entire region (Figure 2). Bacterial artificial chromosome (BAC) and P1-derived artificial chromosome (PAC) clones mapping to the chromosome band 6q13 region were identified from

Table 1 Clinicopathologic, cytogenetic, and molecular cytogenetic data

Case	Age/sex	Location ^a (size in cm)	Karyotype	FISH ^b results
1	29/M	Proximal tibia (1.7 × 4.4 × 5.3)	46,XY,inv(6)(p25q13)[3]/45,X,-Y,inv(6)(p25q13),-13,+mar[2]/46,XY[14]	ABN
2	32/F	Second metatarsus (0.5 × 1.0 × 1.5)	46,XX[18]	N
3a	61/F	Ilium (3.3 × 4.0 × 4.5)	48,XX,+der(6)del(6)(p11.2)del(6)(q12),+der(?)t(6;?:2;6)(?q25;?:q37q14.3;p12p25)[11]/49,idem,+der(6),del(13)(q21q33)[2]/96,idemx2[4]/46,XX[3].ish	N
3b			der(6)(wcp6+),der(?)t(6;?:2;6)(wcp6+,wcp2+,wcp6+)	
4	10/M	Proximal humerus (1.2 × 1.3 × 2.2)	48,XX,+der(6)del(6)(p11.2)del(6)(q12),+der(?)t(6;?:2;6)(?q25;?:q37q14.3;p12p25)[10]/49,idem,+der(6)[5]/46,XX[3]	N
5	21/F	Ilium (5.3 × 5.5 × 7.0)	46,XX[19]	N
6	12/M	Proximal tibia (2.0 × 2.3 × 2.3)	46,XY[7]	N
7	23/M	Ilium N/A	46,XY[20]	N
8a ^c	55/F	Proximal tibia (2.5 × 6.0 × 6.3)	46,XX,t(6;9)(q25;q22),t(7;12)(q32;q13)[15]	N
8b ^c			46,XX,t(6;9)(q25;q22),t(7;12)(q32;q13)[10]	N
9 ^c	37/F	Distal femur N/A	46,XX,del(3)(q23),t(4;6)(q21;q25)[7]	N
10 ^c	13/M	Ilium (5.0 × 7.0 × 10.0)	46,XY,inv(6)(p25q23)t(6;6)(q23;q13)[39],tas(15;21)(p13;p13)[6],tas(3;15)(q29;p13)[5],tas(11;15)(p15;p13)[5],tas(11;15)(p15;p13),r(15)[5][cp39]	ABN
11	44/F	Ulna (1.2 × 1.5 × 2.2)	46,XX,t(1;6)(p35;q25),inv(9)(p11q13)c[17]/46,sl,t(3;4)(p21;p16)[2]/46,XX,inv(9)(p11q13)[1]	NP
12	55/M	Distal tibia (2.1 × 2.6 × 3.4)	46,XY,t(6;9)(q25;q22)[20]	NP
13	47/F	Rib (2.0 × 2.8 × 3.0)	46,XX,t(1;16)(q11;q24),t(9;16)(p23;q12.1),del(13)(q13q22)[16]/46,XX,t(8;14)(q22;q13),t(11;17)(q14;q25)[2]/92sl1x2[2]/46,XX[2]	NP
14	6/F	Great toe, proximal phalanx (0.8 × 0.8 × 1.2)	46,XX,der(6)t(6;6)(q13;q27),der(6)t(6;6)inv(6)(p25q15)[8]/46,XX[12]	ABN

^aAll cases were primary lesions. Cases 3 and 8 included both biopsy and subsequent resection/curettage samples.

^bFISH conducted with the following probes: RP11-560O20, RP11-536O4, RP1-238D15, RP11-209D8, RP1-234P15.

^cThese karyotypes have been reported previously.^{8,10}

N/A, not available; N, normal; ABN, abnormal; NP, not performed.




Figure 1 Chondromyxoid fibroma from case 1 exhibiting a pseudolobulated growth pattern of stellate or spindle-shaped cells in a myxoid stroma with zones of greater cellularity at the periphery of the lobules.




Figure 2 This schematic illustrates the different probe set combinations used to sequentially examine 20 subdivided regions spanning a 6.1 Mb sector. The green boxes indicate probe sets labeled in Spectrum Green and the red boxes indicate probe sets labeled in Spectrum Orange.

the NCBI Map Viewer (<http://www.ncbi.nlm.nih.gov/mapview>) and the Ensembl Genome Browser (<http://www.ensembl.org>). These clones were obtained from Children's Hospital Oakland Research Institute (Oakland, CA, USA) and Research Genetics (Huntsville, AL, USA). Combinations of probe sets were fashioned to flank each defined subregion.

Fluorescence *In Situ* Hybridization

Fluorescence *in situ* hybridization (FISH) studies were performed on clonally abnormal metaphase




Figure 3 Schematic and partial G-banded karyotype illustrating the recurrent 6;9 translocation identified in cases 8 and 12.

cells or cytologic touch preparations of 13 chondromyxoid fibroma samples from 11 patients. Probes were directly labeled by nick translation with either Spectrum Green or Spectrum Orange-dUTP utilizing the manufacturer's protocol (Vysis; Abbott Molecular Inc., Des Plaines, IL, USA). An amount of 1 μ g of DNA for each of two or three probes was combined. All nick translation reagents were then multiplied by the total micrograms of DNA used in the cocktail. Amounts of 200 ng of each probe were hybridized and blocked approximately 15 times with a combination of human Cot-1 DNA (Invitrogen, Carlsbad, CA, USA) and human placental DNA. Spectrum aqua-labeled α -satellite probe for the centromeric region of chromosome 6 (CEP 6 (D6Z1); Abbott Laboratories Inc., Abbott Park, IL, USA) was employed as a ploidy control.

Before hybridization, the touch preparations and *in situ* slides were pretreated in 2 \times saline sodium citrate (SSC) at 72°C for 2 min and in pepsin solution (20 μ l 10% pepsin in 50 ml of 0.1 N hydrochloric acid) at 37°C for 3 min, washed in 1 \times phosphate-buffered saline (PBS) at room temperature for 5 min, fixed in 1% formaldehyde at 4°C for 5 min, and again washed in 1 \times PBS at room temperature for 5 min. The slides were then dehydrated in an ethanol series (70, 85, and 100%) at room temperature for 2 min each and air dried. The cells and probes were codenatured at 75°C for 1 min and incubated at 37°C overnight using the HYBrite denaturation/hybridization system (Vysis). Posthybridization washing was performed in 0.4 \times SSC/




Figure 4 (a) Representative schematic, G-banded and FISH partial karyotypes of the *inv(6)(p25q13)* observed in case 1. With the inversion, the Spectrum Green-labeled proximal probe set (RP11-560O20, RP11-536O4, and RP1-238D15) of 'region 20' has moved to the short arm of chromosome 6. (b) Representative schematic, G-banded and FISH partial karyotypes of the complex rearrangement observed in case 20. The Spectrum Orange-labeled distal probe set (RP11-209D8 and RP1-234P15) of 'region 20' has translocated from one chromosome 6 homologue to the other chromosome 6 homologue at 6q27. The aqua signals in both (a) and (b) represent the centromeric regions of the normal and derivative chromosome 6 homologues.

0.3% NP-40 at 72°C for 2 min, followed by $2 \times$ SSC/0.1% NP-40 at room temperature for 1 min. The slides were air dried in the dark and counterstained with 4',6-diamidino-2-phenylindole (DAPI).

Each BAC or PAC clone was initially analyzed on metaphase and interphase cells of a karyotypically normal donor to confirm hybridization to the anticipated 6q13 locus with lack of cross-hybridization. Hybridization signals for each sample were assessed in 200 interphase nuclei or in 5 metaphase cells with strong, well-delineated signals by two different individuals. As additional controls, normal peripheral blood lymphocytes and cytologic touch preparations of pathologically unremarkable cartilage were simultaneously hybridized with the same probe sets. An interphase cell specimen was interpreted as abnormal for the 6q13 locus if a split of flanking probe signals was detected in >10% of the cells evaluated (more than two standard deviations above

the average false positive rate). Images were acquired using the CytoVision Image Analysis System (Applied Imaging, Santa Clara, CA, USA).

Results

Conventional Cytogenetic Findings

The cytogenetic and FISH findings are summarized in Table 1. Clonal chromosomal abnormalities were detected in 11 of 16 specimens analyzed including 10 involving chromosome 6 (cases 1, 3a, 3b, 8a, 8b, 9, 10, 11, 12, and 13). Rearrangements of 6q13 were identified in three specimens, 6p25 in five specimens, and 6q25 in five (note, an additional two specimens were suspect for a rearrangement of 6q25). Interestingly, two cases exhibited an identical 6;9 translocation (*t(6;9)(q25;q22)*; Figure 3).




Figure 5 Schematic representation of the breakpoint mapping of the *COL12A1* locus. Three BACs, RP11-234P15 (blue), RP11-209D8 (red), and RP1-238D15 (green) cover the 5' region, the middle section, and the 3' region, respectively, of the *COL12A1* gene. Black vertical bars represent the exons and the red vertical bar the promoter region of *COL12A1*. Italicized numbers indicate the genomic position of the BACs and the *COL12A1* gene. By FISH, the 6q13 breakpoint appears to be bound by the RP11-209D8 and RP1-238D15 BAC clones placing its location between exons 13 and 14 of *COL12A1*. The long yellow vertical bar depicts the position of the *COL12A1* breakpoint on chromosome 6q13.

Molecular Cytogenetic Findings

Initial FISH studies were performed on cytologic touch preparations of lesional tissue from case 1 characterized by a cytogenetically confirmed *inv(6)(p25q13)* with 20 separate flanking probe combinations covering all 21 segments from the 6q13 breakpoint, 6.1 Mb region of interest. Only 'region 20' (Spectrum Green-dUTP-labeled proximal probes: RP11-560O20, RP11-536O4, RP1-238D15; Spectrum Orange-dUTP-labeled distal probes: RP11-209D8, RP1-234P15) showed a split of the proximal and distal probe sets indicating a disruption of this 6q13 locus. Subsequent FISH studies performed on case 1 abnormal metaphase cells with the 'region 20' probe set confirmed a disruption of signals with translocation of the proximal probe set to 6p (Figure 4a).

Thirteen additional chondromyxoid fibroma specimens subjected to FISH analysis with the 'region 20' probe set showed a rearrangement of

this locus in two cases (cases 10 and 14). Case 14 exhibited a translocation of the distal probe set from one chromosome 6 homologue to the other chromosome 6 homologue at 6q27 (Figure 4b). A split of one set of probe signals with loss of the probe set signal distal to 'region 20' of the 6q13 breakpoint was identified in case 10. The critical breakpoint bound by RP1-238D15 and RP11-209D8 of 'region 20' at 6q13 is within the *COL12A1* gene (Figure 5). The remaining 11 specimens, none of which demonstrated a 6q13 rearrangement by conventional cytogenetic analysis, were negative by FISH for a rearrangement of this locus.

Discussion

Chondromyxoid fibroma is a rare benign bone tumor composed of immature myxoid mesenchymal tissue with features of early primitive cartilaginous differentiation.⁴ Chondromyxoid fibroma most commonly

Table 2 Chromosomal findings in chondromyxoid fibroma

No.	Karyotype	Reference
1	46,XY,t(2;13)(p14;q33)[3]/47,idem,+5[6]/46,XY[11]	Bridge et al ⁵
2	46,XX,der(2)ins(5;2)(q13;p21p25),der(2)ins(5;2)(q13;p21p25),der(5)ins(5;2)(q13;p21p25)[5]/46,XX[28]	Tarkkanen et al ⁶
3	46,XX,add(3)(p12),der(6)t(3;6)(p22;q?24)ish der(3)t(3;6)(p12;q24)(wcp3+,wcp6+), der(6)t(3;6)(p22;q24)(wcp6+,wcp3+,wcp6+,wcp3+)[17]/46,XX[3]	Halbert et al ⁷
4	46,XY,inv(6)(p25q23)t(6;6)(q23;q13)[39],tas(15;21)(p13;p13)[6],tas(3;15)(q29;p13)[5], tas(11;15)(p15;p13)[5],tas(11;15)(p15;p13),r(15)[5][cp39]	Sawyer et al ⁸
5	46,XY,inv(6)(p25q13)[15]	Granter et al ⁹
6	46,XY,der(6)add(6)(p23)add(6)(q12),der(6)inv(6)(p25q13)add(6)(q26),del(12)(q22q24)[30]	Granter et al ⁹
7	46,XX,add(6)(q13),add(7)(q21)[10]	Granter et al ⁹
8	46,XX,del(6)(q13q23)[4]	Granter et al ⁹
9a	46,XX,t(6;9)(q25;q22),t(7;12)(q32;q13)[15]	Safar et al ¹⁰
9b	46,XX,t(6;9)(q25;q22),t(7;12)(q32;q13)[10]	Safar et al ¹⁰
10	46,XX,del(3)(q23),t(4;6)(q21;q25)[7]	Safar et al ¹⁰
11	46,XX,ins(19;6)(p13.1;q13q25)[19]/46,XX[1]	Smith et al ¹³
12	46,XX,del(6)(?q21?q23),add(7)(q21)	Tallini et al ¹¹
13	46,XY,del(6)(q15),der(6)t(6;6)(q15;q27)inv(6)(p25q13)/46,XY	Tallini et al ¹¹
14	46,XY,inv(6)(p25q13)[15]/46,XY[19]	Sjögren et al ¹²
15	46,XX,t(1;5)(p13;p13)[18]/46,XX[3]	Armah et al ¹⁴
16	45,XY,ehrb(6)(q13),der(14;21)(q10;q10)[6]/46,XY[34]	Jhala et al ¹⁵
17	46,XY,inv(6)(p25q13)[3]/45,X,-Y,inv(6)(p25q13),-13,+mar[2]/46,XY[14]	Current study
18a	48,XX,+der(6)del(6)(p11.2)del(6)(q12),+der(?)t(6;?;2;6)(?q25;?;q37q14.3;p12p25)[11]/49, idem,+der(6),del(13)(q21q33)[2]/96,idemx2[4]/46,XX[3].ish der(6)(wcp6+),der(?)t(6;?;2;6)(wcp6+,wcp2+,wcp6+)	Current study
18b	48,XX,+der(6)del(6)(p11.2)del(6)(q12),+der(?)t(6;?;2;6)(?q25;?;q37q14.3;p12p25)[10]/49,idem, +der(6)[5]/46,XX[3]	Current study
19	46,XX,t(1;6)(p35;q25),inv(9)(p11q13)c[17]/46,sl,t(3;4)(p21;p16)[2]46,XX,inv(9)(p11q13)[1]	Current study
20	46,XX,t(6;9)(q25;q22)[20]	Current study
21	46,XX,t(1;16)(q11;q24),t(9;16)(p23;q12.1),der(13)(q13;q22)[16]/46,XX,t(8;14)(q22;q13),t(11;17) (q14;q25)[2]/92sl1x2[2]/46,XX[2]	Current study
22	46,XX,der(6)t(6;6)(q13;q27),der(6)t(6;6)inv(6)(p25q15)[8]/46,XX[12]	Current study

arises as an eccentrically located lytic lesion in the metaphysis of long tubular bones.² Histopathologically, chondromyxoid fibroma displays a pseudolobulated architecture with peripheral condensation of the neoplastic cells.^{2,4} A thorough coordinated evaluation of clinical, radiological, and histological features generally leads to the correct diagnosis. In some cases, however, chondromyxoid fibroma may be mistaken for chondrosarcoma because of overlapping histopathologic traits including occasional pronounced cytologic atypia. Moreover, the use of minimally invasive biopsies to diagnose bone tumors has become increasingly common, and this shift has created additional challenges. Recognition of novel diagnostic markers such as a tumor-specific chromosomal anomaly or gene rearrangement(s) could be useful in this respect.

Cytogenetic studies of chondromyxoid fibroma are few. To date, including the 11 specimens at our institution, 22 chondromyxoid fibroma specimens have reportedly shown clonal karyotypic anomalies (Table 2).^{5–15} A diploid or near-diploid chromosomal complement has been observed in all cases analyzed. Chromosomal abnormalities involving 6q13 appear most frequent (11/22 specimens, 50%) followed by 6p25 (9/22, 41%) and 6q25 (8/22, 36%). An identical pericentric inversion, inv(6)(p25q13), has been detected in four chondromyxoid fibromas.^{9,11,12} In accordance with previous reports, this aberration was also observed in a subset

of the 6q13 aberrant tumors of the present series (cases 1 and 20; as a component of a more complex anomaly in the latter case). In addition, a novel translocation, t(6;9)(q25;q22), was identified as the sole anomaly in case 12 and as accompanied by a 7;12 translocation as the only other abnormality in case 8,¹⁰ suggesting that it may represent a second diagnostic marker of chondromyxoid fibroma.

Given that the cytogenetic findings of this study and a review of the literature indicated that the 6q13 locus is most commonly rearranged in chondromyxoid fibroma and likely harbors an oncogene of etiologic importance in this entity, efforts to further investigate this breakpoint were conducted. Meta-phase and interphase FISH analyses revealed the key breakpoint lies within a 250 kb region located approximately 75.8–75.9 Mb from the telomere of 6p and flanked by RP1-238D15 and RP11-209D8 at 6q13. One gene, collagen type XII alpha 1 (*COL12A1*), is localized to this region of overlap (<http://www.ncbi.nlm.nih.gov/mapview>; <http://www.ensembl.org>), strongly suggesting its involvement in the development of chondromyxoid fibroma. Interestingly, another collagen gene, *COL15A1*, resides at 9q22¹⁸ and it could be speculated that this gene is involved in the recurrent 6;9 translocation identified in CMF cases lacking the inv(6)(p25q13).

The collagens constitute a large group of extracellular matrix proteins that can be divided into several distinct families. The *COL12A1* gene

encodes the alpha chain of type XII collagen. Type XII collagen is a member of the fibril-associated collagens with interrupted triple helices (FACIT) family and is composed of two short collagenous triple-helical domains and three non-triple-helical domains.¹⁹ Although type XII collagen is expressed in a variety of connective tissues including articular and epiphyseal cartilage,^{20–24} its exact function remains poorly understood.

Recently, Storiuzzi *et al*²⁵ demonstrated rearrangements of the *COL12A1* and *COL4A5* (at Xq22) gene loci in subungual exostoses with a t(X;6)(q22;q13-14). However, as these two genes are oriented in opposite directions (*COL12A1* is transcribed from telomere to centromere whereas *COL4A5* is transcribed from centromere to telomere), the authors concluded it was unlikely that these two genes fused to create a functional chimeric gene. Rather, they suggested that *COL12A1* creates a fusion transcript with a different gene on the X chromosome, possibly *IRS4*.

On a similar theme, a different collagen associated gene *COL1A1* (at 17q22), is fused to *PDGFB* (at 22q13) and *USP6* (at 17p13) in dermatofibrosarcoma protuberans/giant cell fibroblastoma and aneurysmal bone cyst, respectively.^{26,27} For these neoplasms, the promoter region of *COL1A1* is juxtaposed to the coding sequence of the fusion partner, thereby contributing to its transcriptional upregulation by promoter swapping. If the same molecular mechanism were to be applied to chondromyxoid fibroma, then it would be expected that a fusion transcript derived from the rearrangements involving 6q13 (such as the inv(6)(p25q13) identified in a subset of these tumors) would be pathogenetic. In this study, attempts to use the very limited quantity of extracted RNA available for identification of aberrant *COL12A1* transcripts by RACE-PCR experiments failed (data not shown).

In conclusion, we have identified a consistent rearrangement of the *COL12A1* gene locus in a subset of chondromyxoid fibromas karyotypically exhibiting 6q13 aberrations. The FISH probe sets utilized in this study represent an alternative approach for detecting 6q13 (*COL12A1*) rearrangements in nondividing cells of chondromyxoid fibroma as a potential adjunct in diagnostically challenging cases. In addition, we have discovered a second novel rearrangement, t(6;9)(q25;q22), as nonrandom in chondromyxoid fibroma. Additional studies afforded by sufficient fresh or frozen samples of this rare neoplasm are needed to further explicate how *COL12A1* transcription is affected, and its potential gene partners.

Acknowledgements

This work was supported in part by Eppley Pediatric Award, Nebraska State Department of Health (LB595) and NIH (P30 CA36727). Dr Jun Nishio

and Dr Taketoshi Yasuda were supported by the Gladys Pearson Fellowship in Pediatric Cancer and Genetics. We thank Ms Kimberly Christian for her expert secretarial assistance and Ms Marilu Nelson, Ms Renae Streblow, Ms Jamie Woodard, and Dr Dali Huang for their technical assistance.

Disclosure/conflict of interest

The authors declared no conflict of interest.

References

- Jaffe HL, Lichtenstein L. Chondromyxoid fibroma of bone: distinctive benign tumor likely to be mistaken especially for chondrosarcoma. *Arch Pathol* 1948;45:541–551.
- Unni KK, Inwards CY, Bridge JA, *et al* Chondromyxoid fibroma. In: Silverberg SG, Sobin LH (eds) *AFIP Atlas of Tumor Pathology, Tumor of the Bones and Joints*. ARP Press: Silver Spring, 2005. pp 67–73.
- Wu CT, Inwards CY, O’Laughlin S, *et al* Chondromyxoid fibroma of bone: a clinicopathologic review of 278 cases. *Hum Pathol* 1998;29:438–446.
- Ostrowski ML, Spjut HJ, Bridge JA. Chondromyxoid fibroma. In: Fletcher CDM, Unni KK, Mertens F (eds) *WHO Classification of Tumours, Pathology and Genetics of Tumours of Soft Tissue and Bone*. IARC Press: Lyon, France, 2002. pp 243–245.
- Bridge JA, Sanger WG, Neff JR. Translocations involving chromosomes 2 and 13 in benign and malignant cartilaginous neoplasms. *Cancer Genet Cytogenet* 1989;38:83–88.
- Tarkkanen M, Bohling T, Helio H, *et al* A recurrent chondromyxoid fibroma with chromosome aberrations ins(5;2)(q13;p21p25) and 2p deletion: a case report. *Cancer Genet Cytogenet* 1993;65:141–146.
- Halbert AR, Harrison WR, Hicks MJ, *et al* Cytogenetic analysis of a scapular chondromyxoid fibroma. *Cancer Genet Cytogenet* 1998;104:52–56.
- Sawyer JR, Swanson CM, Lukacs JL, *et al* Evidence of an association between 6q13-21 chromosome aberrations and locally aggressive behavior in patients with cartilage tumors. *Cancer* 1998;82:474–483.
- Granter SR, Renshaw AA, Kozakewich HP, *et al* The pericentromeric inversion, inv(6)(p25q13), is a novel diagnostic marker in chondromyxoid fibroma. *Mod Pathol* 1998;11:1071–1074.
- Safar A, Nelson M, Neff JR, *et al* Recurrent anomalies of 6q25 in chondromyxoid fibroma. *Hum Pathol* 2000;31:306–311.
- Tallini G, Dorfman H, Brys P, *et al* Correlation between clinicopathological features and karyotype in 100 cartilaginous and chordoid tumours: a report from the Chromosomes and Morphology (CHAMP) Collaborative Study Group. *J Pathol* 2002;196:194–203.
- Sjögren H, Orndal C, Tingby O, *et al* Cytogenetic and spectral karyotype analyses of benign and malignant cartilage tumours. *Int J Oncol* 2004;24:1385–1391.
- Smith CA, Magenis RE, Himoe E, *et al* Chondromyxoid fibroma of the nasal cavity with an interstitial insertion between chromosomes 6 and 19. *Cancer Genet Cytogenet* 2006;171:97–100.
- Armah HB, McGough RL, Goodman MA, *et al* UNM. Chondromyxoid fibroma of rib with a novel chromo-

- somal translocation: a report of four additional cases at unusual sites. *Diagn Pathol* 2007;2:44.
- 15 Jhala D, Coventry S, Rao P, *et al* Juvenile juxtacortical chondromyxoid fibroma of bone: a case report. *Hum Pathol* 2008;39:960–965.
 - 16 Althof PA, Ohmori K, Zhou M, *et al* Cytogenetic and molecular cytogenetic findings in 43 aneurysmal bone cysts: aberrations of 17p mapped to 17p13.2 by fluorescence *in situ* hybridization. *Mod Pathol* 2004;17:518–525.
 - 17 Shaffer LG, Tommerup N, (Eds) *An International System for Human Cytogenetic Nomenclature*. S Karger: Basel, 2005.
 - 18 Huebner K, Cannizzaro LA, Jabs EW, *et al* Chromosomal assignment of a gene encoding a new collagen type (COL15A1) to 9q21-q22. *Genomics* 1992;14:220–224.
 - 19 Oh SP, Taylor RW, Gerecke DR, *et al* The mouse $\alpha 1$ (XII) and human $\alpha 1$ (XII)-like collagen genes are localized on mouse chromosome 9 and human chromosome 6. *Genomics* 1992;14:225–231.
 - 20 Watt SL, Lunstrum GP, McDonough AM, *et al* Characterization of collagen types XII and XIV from fetal bovine cartilage. *J Biol Chem* 1992;267:20093–20099.
 - 21 Oh SP, Griffith CM, Hay ED, *et al* Tissue-specific expression of type XII collagen during mouse embryonic development. *Dev Dyn* 1993;196:37–46.
 - 22 Walchli C, Koch M, Chiquet M, *et al* Tissue-specific expression of the fibril-associated collagens XII and XIV. *J Cell Sci* 1994;107:669–681.
 - 23 Dharmavaram RM, Huynh AI, Jimenez SA. Characterization of human chondrocyte and fibroblast type XII collagen cDNAs. *Matrix Biol* 1998;16:343–348.
 - 24 Gregory KE, Keene DR, Tufa SF, *et al* Developmental distribution of collagen type XII in cartilage: association with articular cartilage and the growth plate. *J Bone Miner Res* 2001;16:2005–2016.
 - 25 Storiuzzi CT, Wozniak A, Panagopoulos I, *et al* Rearrangements of the COL12A1 and COL4A5 genes in subungual exostosis: molecular cytogenetic delineation of the tumor-specific translocation t(X;6)(q13-14;q22). *Int J Cancer* 2006;118:1972–1976.
 - 26 Simon M-P, Pedeutour F, Sirvent N, *et al* Deregulation of the platelet-derived growth factor β -chain gene via fusion with collagen gene COL1A1 in dermatofibrosarcoma protuberans and giant cell fibroblastoma. *Nat Genet* 1997;15:95–98.
 - 27 Oliveira AM, Perez-Atayde AR, Dal Cin P, *et al* Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes. *Oncogene* 2005;24:3419–3426.